Brief: Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675
05/03/2025 14:29
March 5 (Reuters) - Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY EVALUATING NBI-1140675, A SECOND-GENERATION VMAT2 INHIBITOR, IN HEALTHY ADULTS Source text: ID:nPn1L9NVKa Further company coverage: NBIX.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall